Oncology Burst
FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products
FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
We are delighted to announce EORTC’s participation at the ESTRO Congress 2024 taking place from 3 to 7 May 2024 in Glasgow, UK.
Here, we summarize an analysis of CD19-targeting CAR T-cell therapy in patients with PCNSL or SCNSL, presented by Ossami Saidy during the 50th Annual Meeting…
Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.
Georgina V. Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia, discusses the Phase II SECOMBIT (NCT02631447) trial, which evaluated the best…
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.
Unfortunately the website is temporarily unavailable. We are working to fix the issue and it should be back online shortly. We apologise for an inconvenience…
The integration of Artificial Intelligence (AI) in oncology is a developing field, impacting the doctor-patient relationship and the efficacy of cance…
Facing close competition for re-election and concerted pushback from the tobacco industry and its allies, the US Government administration of President Joe Biden has delayed…